{"id":"NCT00964028","sponsor":"GlaxoSmithKline","briefTitle":"Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)","officialTitle":"Safety and Reactogenicity of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) in Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12-01","primaryCompletion":"2010-04-12","completion":"2010-04-12","firstPosted":"2009-08-24","resultsPosted":"2017-04-10","lastUpdate":"2018-06-06"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Haemophilus Influenzae Type b","Acellular Pertussis","Diphtheria","Tetanus","Poliomyelitis"],"interventions":[{"type":"BIOLOGICAL","name":"Infanrix™-IPV/Hib","otherNames":[]}],"arms":[{"label":"INFANRIX-IPV/HIB M2-M3-M4 GROUP","type":"EXPERIMENTAL"},{"label":"INFANRIX-IPV/HIB M3-M4-M5 GROUP","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and reactogenicity of Infanrix-IPV/Hib given as a three-dose primary vaccination course to healthy infants at 2-3-4 or 3-4-5 months of age.","primaryOutcome":{"measure":"Number of Subjects With Any Solicited Local Symptoms","timeFrame":"During the 4-day (Days 0-3) follow-up period after each dose and across doses","effectByArm":[{"arm":"Infanrix-IPV/Hib M2-M3-M4 Group","deltaMin":4,"sd":null},{"arm":"Infanrix-IPV/Hib M3-M4-M5 Group","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"60 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Fever","Irritability","Drowsiness","Loss of appetite","Upper respiratory tract infection"]}}